• Latest Posts

Serious Genetic Diseases have a New CRISPR Dream Duo Venture worth in Excess of €275M

Oxford’s Nightstar Gene Therapy for Blindness in Men Shines with $35M Fundraiser

Apitope relocates to Wales after €12M series B financing round

Leading Cause of blindness has new US & EU Orphan Drug Designation Immunotherapy

Oh dear, Allergan is doing its 4th product recall in 2015 …

Aging-diseases expert Biophytis launches its IPO in Paris


Vision specialist Gensight eyes a €90M IPO on NASDAQ

Bayer set a strategic alliance with J. Hopkins in retinal diseases

AYOXXA raises its sights with a new agreement to develop ophthalmic diagnostic tools